UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...

Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when ...

Eli Lilly and Company (LLY) on Tuesday said that its cancer drug Jaypirca was more effective than AbbVie’s drug Imbruvica in ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...